Xofigo (radium Ra 223 dichloride) is a systemic radiopharmaceutical. Radium is chemically similar to calcium and is taken up by bones in places where bone is actively growing, as in prostate cancer bone metastases. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: combination, radium-223, therapy, Xofigo | Leave a comment »
Many years ago, it was discovered that a moderate increase in tissue temperature can markedly improve the cancer cell killing power of ionizing radiation. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: combination, hyperthermia, practise, radiation, theory, therapy | 1 Comment »
An article published on line last year in Anticancer Research has just come to our attention. It puts forward the relatively simple proposal that by combining androgen deprivation therapy (ADT) with estrogen deprivation therapy (EDT) we might be able to significantly impact the risk for development of castration-resistant prostate cancer (CRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: androgen, combination, deprivation, estrogen | 17 Comments »
A newly published article in the journal Science Translational Medicine has questioned the merits of treating prostate cancer patients with immunotherapies while they are simultaneously being treated with medical forms of castration (androgen deprivation therapy or ADT), chemotherapy, and/or radiation therapy. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, benefit, chenotherapy, combination, immunotherapy, radiation, risk, timing | 6 Comments »
There is an interesting report on the OncLive web site of a lecture by Dr. Robert Dreicer given just a few weeks ago and dealing with the sequential and combination use of new agents like abiraterone acetate, enzalutamide and others for the treatment of advanced and progressive forms of prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, combination, enzalutamide, radium-223, sequencing, sipuleucel-T | 14 Comments »
A media release issued earlier today by Barvarian Nordic (the developer of Prostvac®) gives us an inkling of where we may be headed in the development of combination therapies for the management of late stage (and maybe even earlier stage) forms of prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castrate-resistant, combination, immunotherapeutic, ipilimumab, mCRPC, outcome, Prostvac, survival | Leave a comment »
Monique Roobol and her colleagues continue to mine data from the ERSPC and other major trials in a serious attempt to describe processes that would allow us to identify the vast majority of clinically significant prostate cancers while avoiding the unnecessary diagnosis and over-treatment of indolent disease. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, chemoprevention, combination, Diagnosis, dutasteride, risk, screening | 1 Comment »
Docetaxel + prednisone is the current standard treatment for men with castration-resistant prostate cancer (CRPC). However, the survival benefit of this form of treatment is small compared to older forms of therapy. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant prostate cancer, combination, CRPC, docetaxel, ketoconazole | Leave a comment »
In September this year, writing from the 50th annual meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), Dr. Eyad Abu-Isa addressed breaking news of a Scandinavian trial comparing radiotherapy + hormone therapy to radiotherapy alone in the treatment of locally advanced prostate cancer. The complete results of this study in were just published in The Lancet . … READ MORE …
Filed under: Management, Treatment | Tagged: combination, hormone therapy, radiotherapy | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 